RAB0521
Bovine IL2 / Interleukin-2 ELISA Kit
for serum, plasma and cell culture supernatants
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
NACRES:
NA.32
UNSPSC Code:
41116158
Gene information:
bovine ... IL2(280822)
Input:
sample type serum
sample type cell culture supernatant(s)
sample type plasma
sample type cell culture supernatant(s)
sample type plasma
Species reactivity:
bovine
Storage temp.:
−20°C
Shipped in:
wet ice
species reactivity
bovine
packaging
kit of 96 wells (12 strips x 8 wells)
technique(s)
ELISA: suitable
input
sample type serum
sample type cell culture supernatant(s)
sample type plasma
assay range
inter-assay cv: <10%
intra-assay cv: <12%
sensitivity: 0.2 ng/mL
detection method
colorimetric
shipped in
wet ice
storage temp.
−20°C
Gene Information
bovine ... IL2(280822)
General description
This ELISA antibody pair detects bovine Interleukin-2.
Application
For research use only. Not for use in diagnostic procedures.
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)
Other Notes
A sample Certificate of Analysis is available for this product.
Please type the word sample in the text box provided for lot number.
Please type the word sample in the text box provided for lot number.
Kit Components Also Available Separately
Product No.
Description
SDS
signalword
Warning
hcodes
pcodes
Hazard Classifications
Met. Corr. 1
Storage Class
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Tatsuo Matsuda et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 24(21), 5357-5367 (2018-05-04)
Purpose: Current evolution of cancer immunotherapies, such as immune checkpoint blockade, has implicated neoantigens as major targets of anticancer cytotoxic T cells. Adoptive T-cell therapy with neoantigen-specific T-cell receptor (TCR)-engineered T cells would be an attractive therapeutic option for advanced
Pratiksha Gulati et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 24(16), 3981-3993 (2018-05-12)
Purpose: Combination therapy of adoptively transferred redirected T cells and checkpoint inhibitors aims for higher response rates in tumors poorly responsive to immunotherapy like malignant pleural mesothelioma (MPM). Only most recently the issue of an optimally active chimeric antigen receptor
Sneha Ramakrishna et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 25(17), 5329-5341 (2019-05-22)
Chimeric antigen receptor T-cell (CART) therapy targeting CD22 induces remission in 70% of patients with relapsed/refractory acute lymphoblastic leukemia (ALL). However, the majority of post-CD22 CART remissions are short and associated with reduction in CD22 expression. We evaluate the implications
Zhengping Hu et al.
Scientific reports, 8(1), 217-217 (2018-01-11)
The increased PD-L1 induces poorer prognosis in melanoma. The treatment with PD-1/PD-L1 antibodies have a low response rate. The combination immunotherapies are the encouraging drug development strategy to receive maximal therapeutic benefit. In this study, we investigated the enhanced antitumor
Sarah Ahn et al.
Cancer immunology research, 7(5), 773-783 (2019-03-08)
Tumors are inherently heterogeneous in antigen expression, and escape from immune surveillance due to antigen loss remains one of the limitations of targeted immunotherapy. Despite the clinical use of adoptive therapy with chimeric antigen receptor (CAR)-redirected T cells in lymphoblastic
Related Content
Instructions
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service